Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia

Muhammad Rizwan Khawaja, Susan Perkins, Jennifer E. Schwartz, Michael Robertson, Patrick J. Kiel, Hamid Sayar, Elizabeth A. Cox, Gail Vance, Sherif Farag, Larry Cripe, Robert Nelson

Research output: Contribution to journalArticle

Abstract

We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse. Am. J. Hematol. 90:97-99, 2015.

Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalAmerican Journal of Hematology
Volume90
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Acute Myeloid Leukemia
Cyclophosphamide
Survival
Recurrence
Disease-Free Survival
Multivariate Analysis
fludarabine

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. / Khawaja, Muhammad Rizwan; Perkins, Susan; Schwartz, Jennifer E.; Robertson, Michael; Kiel, Patrick J.; Sayar, Hamid; Cox, Elizabeth A.; Vance, Gail; Farag, Sherif; Cripe, Larry; Nelson, Robert.

In: American Journal of Hematology, Vol. 90, No. 2, 01.02.2015, p. 97-99.

Research output: Contribution to journalArticle

Khawaja, Muhammad Rizwan ; Perkins, Susan ; Schwartz, Jennifer E. ; Robertson, Michael ; Kiel, Patrick J. ; Sayar, Hamid ; Cox, Elizabeth A. ; Vance, Gail ; Farag, Sherif ; Cripe, Larry ; Nelson, Robert. / Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. In: American Journal of Hematology. 2015 ; Vol. 90, No. 2. pp. 97-99.
@article{f6b458f0a131493ea5bd3450ab9b82cb,
title = "Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia",
abstract = "We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse. Am. J. Hematol. 90:97-99, 2015.",
author = "Khawaja, {Muhammad Rizwan} and Susan Perkins and Schwartz, {Jennifer E.} and Michael Robertson and Kiel, {Patrick J.} and Hamid Sayar and Cox, {Elizabeth A.} and Gail Vance and Sherif Farag and Larry Cripe and Robert Nelson",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/ajh.23875",
language = "English",
volume = "90",
pages = "97--99",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia

AU - Khawaja, Muhammad Rizwan

AU - Perkins, Susan

AU - Schwartz, Jennifer E.

AU - Robertson, Michael

AU - Kiel, Patrick J.

AU - Sayar, Hamid

AU - Cox, Elizabeth A.

AU - Vance, Gail

AU - Farag, Sherif

AU - Cripe, Larry

AU - Nelson, Robert

PY - 2015/2/1

Y1 - 2015/2/1

N2 - We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse. Am. J. Hematol. 90:97-99, 2015.

AB - We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse. Am. J. Hematol. 90:97-99, 2015.

UR - http://www.scopus.com/inward/record.url?scp=84921415407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921415407&partnerID=8YFLogxK

U2 - 10.1002/ajh.23875

DO - 10.1002/ajh.23875

M3 - Article

VL - 90

SP - 97

EP - 99

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -